EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic nicotinamide mononucleotide administration to mitigate post-cardiac arrest brain injury in mice

Daiki Kaito iD, Tomoyoshi Tamura iD, Sayuri Suzuki, Ryutaro Onishi, Kenji F Tanaka, Jun Yoshino, Tadashi Matsuoka, Katsuya Maeshima iD, Junichi Sasaki iD, Koichiro Homma iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0334608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Daiki Kaito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan. Hauptthemen laut MEDLINE: Nicotinamide Mononucleotide, Heart Arrest, Brain Injuries, Neuroprotective Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Astellas Foundation for Research on Metabolic Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-cardiac arrest brain injury (PCABI) is the leading cause of death and disability following cardiac arrest (CA). Nicotinamide adenine dinucleotide (NAD + ) depletion after CA contributes to neuronal injury, while nicotinamide mononucleotide (NMN) replenishes NAD + and may provide neuroprotection via sirtuin activation. This study aimed to investigate the effects of systemic NMN administration on neurological function, survival, and sirtuin-3 (SIRT3) levels in the brain post-CA. In adult male mice (C57BL/6NCrSlc, 10–15 weeks old), 10-min CA was induced by intravenous potassium chloride injection followed by cardiopulmonary resuscitation. NMN (60 mg/kg body weight) or normal saline (control) was randomly administered by intraperitoneal injection immediately after the return of spontaneous circulation (ROSC) and 24 and 48 h post-CA. Brain NAD + and adenosine triphosphate (ATP) levels, neurological function score (NFS), survival, histological neuronal injury, and brain gene expression and protein levels were measured. Brain NAD + levels decreased at 2 h post-ROSC and NMN significantly increased brain NAD + and ATP levels. At 48 h post-CA, surviving mice in the NMN group exhibited significantly higher NFS (control: 8 [IQR: 4–12] vs. NMN: 12 [IQR: 9–12], p = 0.03) and less severe hippocampal neuronal injury compared with controls. Moreover, the NMN group showed significantly higher 7-day survival rate (control: 22.2% [4/18] vs. NMN: 61.1% [11/18], p = 0.03) and brain SIRT3 levels (control: 17.7 ± 3.6 vs. NMN: 34.5 ± 4.4 pg/mg protein, p = 0.01). In conclusion, systemic NMN administration after ROSC attenuates PCABI. The increased brain ATP levels and SIRT3 upregulation may suggest the usefulness of NMN for improving mitochondrial function and contributing to neuroprotection. NAD + supplementation with NMN is a promising therapeutic approach against PCABI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide MononucleotideHeart ArrestBrain InjuriesNeuroprotective AgentsAnimalsMaleMiceSirtuin 3NADMice, Inbred C57BLAdenosine TriphosphateBrain

Substanzen

Nicotinamide MononucleotideSirtuin 3NADAdenosine TriphosphateSirt3 protein, mouseNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
  • Division of Brain Sciences, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.
  • The Center for Integrated Kidney Research and Advance (IKRA), Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.

ORCID-Profile: Daiki Kaito, Tomoyoshi Tamura, Katsuya Maeshima, Junichi Sasaki, Koichiro Homma

Förderung

  • Japan Society for the Promotion of Science
  • Astellas Foundation for Research on Metabolic Disorders

Zitieren

APA

Kaito, D., Tamura, T., Suzuki, S., Onishi, R., Tanaka, K. F., Yoshino, J., Matsuoka, T., Maeshima, K., Sasaki, J., & Homma, K. (2025). Systemic nicotinamide mononucleotide administration to mitigate post-cardiac arrest brain injury in mice. PLOS One. https://doi.org/10.1371/journal.pone.0334608

Vancouver

Kaito D, Tamura T, Suzuki S, Onishi R, Tanaka KF, Yoshino J, et al. Systemic nicotinamide mononucleotide administration to mitigate post-cardiac arrest brain injury in mice. PLOS One. 2025. doi:10.1371/journal.pone.0334608

BibTeX
@article{Kaito2025,
  author = {Kaito, Daiki and Tamura, Tomoyoshi and Suzuki, Sayuri and Onishi, Ryutaro and Tanaka, Kenji F and Yoshino, Jun and Matsuoka, Tadashi and Maeshima, Katsuya and Sasaki, Junichi and Homma, Koichiro},
  title = {Systemic nicotinamide mononucleotide administration to mitigate post-cardiac arrest brain injury in mice},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0334608}
}
Kostenlos starten →